A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction

Prior treatment

• Have myocardial infarction, coronary artery bypass graft surgery or other major cardiovascular surgery, stroke in the last 90 days prior to screening
• Have acute decompensated heart failure requiring IV diuretics within 12 weeks prior to screening

Other illness

• Have cardiac amyloidosis, accumulation diseases (e.g., haemochromatosis, Fabry disease), muscular dystrophies, hypertrophic cardiomyopathy, pericardial constriction, or complex congenital heart disease.
• Have a history or presence of hepatic, pancreatic, or biliary tract disorders
• Have a history of malignancy or active malignancy at screening.

Age

• Have not had age-appropriate cancer screening as recommended by the American Cancer Society and per medical judgment

Other

• Have any moderate-to-severe stenosis of the mitral and/or aortic valve or moderate-to severe or greater mitral and/or aortic regurgitation.

• Are males and in agreement to follow contraceptive requirements, or women of non-child-bearing potential
• Have a body mass index (BMI) of \</= 45.0 kilograms per square meter (kg/m²)
• Have chronic stable heart failure (New York Heart Association (NYHA) classification II and III) on guideline directed heart failure therapy for at least 6 months prior to enrolment
• Have not changed optimal guideline directed therapy in the last 1 month prior to screening, If treated with oral diuretics, dose must be stable for at least 2 weeks prior to screening
• Have Left Ventricular Ejection Fraction (LVEF) \< 40%
• Have a record of N-terminal pro b-type natriuretic peptide (NT-ProBNP) ≥ 200 picograms per millilitre (pg/mL) or a BNP value of \>/= 60 pg/mL within the past 12 months prior to screening